HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ethyl 4-chloro-3-hydroxybutanoate (CHBE)

an optically active compound

Also Known As:

CHBE; 4-chloro-3-hydroxybutyric acid ethyl ester

Networked: 11 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - ethyl 4-chloro-3-hydroxybutanoate: 11
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - ethyl 4-chloro-3-hydroxybutanoate: 11

Experts

1.	Hadziyannis, S J: 2 articles (01/2006 - 07/2001)
2.	Manesis, E K: 2 articles (01/2006 - 07/2001)
3.	Calvo, Henar: 1 article (01/2022)
4.	Chandrala, Lakshmana: 1 article (01/2022)
5.	Chen, Si: 1 article (01/2022)
6.	Dalekos, George: 1 article (01/2022)
7.	Gatselis, Nikolaos: 1 article (01/2022)
8.	Ghosh, Baishakhi: 1 article (01/2022)
9.	González-Praetorius, Alejandro: 1 article (01/2022)
10.	Hadziyannis, Emilia: 1 article (01/2022)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2023 - "The results revealed that daily body weight gain improved (P < 0.05) by 18.64% and 23.94%, and feed conversion ratio improved by 3.74% and 17.91% than control, respectively, during 30-86 days of age in CHB and CHBE groups. "
2.	Chronic Hepatitis B 01/01/2022 - "Hepatitis B virus (HBV)-specific CD8+ cell response restoration during nucleos(t)ide analogue (NUC) treatment could lead to off-treatment HBV control in e-antigen-negative chronic hepatitis B (CHBe(-)). " 01/01/2022 - "Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). " 01/01/2007 - "Serum HBsAg was quantified by ADVIA Centaur in 63 patients with HBeAg-negative chronic hepatitis B (CHBe-). " 07/01/2001 - "In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. " 01/01/2013 - "We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B. "
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2022 - "Here, we show that both CS-exposed and COPD-patient derived epithelia (CHBE) display quantitative evidence of cellular plasticity, with loss of specialized apical features and a transcriptional profile suggestive of partial epithelial-to-mesenchymal transition (pEMT), albeit with distinct cell motion indicative of cellular unjamming. " 01/28/2019 - "The microRNA profiles in primary bronchial epithelial cells from asthma (AHBE) and COPD (CHBE) patients and healthy subjects (NHBE) were analyzed with next-generation sequencing (NGS) and the significant microRNA changes common in AHBE and CHBE were extracted. "
4.	Hepatocellular Carcinoma (Hepatoma) 01/01/2022 - "Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). "
5.	Fibrosis (Cirrhosis) 01/01/2013 - "A Markov model was constructed to follow hypothetical cohorts of treated and untreated 40-year-old CHBe+ and CHBe- patients and 50-year-old patients with compensated cirrhosis. "

Related Drugs and Biologics

1.	Hepatitis B e Antigens
2.	Lamivudine (Epivir)
3.	Interferons
4.	MicroRNAs (MicroRNA)
5.	Interferon-alpha (Interferon Alfa)
6.	Hepatitis B Surface Antigens (HBsAg)
7.	DNA (Deoxyribonucleic Acid)
8.	Tenofovir (Viread)
9.	entecavir